JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.18 -1.33

Buy Sell

Overview

Share price change

24h

Current

Min

8.08

Max

8.29

Key metrics
By Trading Economics
Income	27M 32K
Sales	14M 146M
Profit margin	0.022
Employees	580
EBITDA	22M 21M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+106.34% upside

Dividends
By Dow Jones
Next Earnings	3 lis 2025

Market Stats
By TradingEconomics
Market Cap	-19M 1.8B
Previous open	9.51
Previous close	8.18

News Sentiment

By Acuity

39%

61%

125 / 374 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 sie 2025, 17:49 UTC

Major Market Movers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 sie 2025, 17:18 UTC

Major Market Movers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 sie 2025, 16:25 UTC

Earnings

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 sie 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 sie 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 sie 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 sie 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 sie 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 sie 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 sie 2025, 20:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 sie 2025, 20:22 UTC

Earnings

Exodus Movement 2Q Rev $25.8M >EXOD

11 sie 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 sie 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 sie 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 sie 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 sie 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 sie 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 sie 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 sie 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 sie 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 sie 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

106.34% upside

12 Months Forecast

Average 16.92 USD 106.34%

High 30 USD

Low 8.5 USD

Based on 6 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

125 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.